Drugs-for-viral-infections-anti-viral

Stepwise Approach of Dengue Case ManagementPatients Group A: These are patients who are dengue patients without warning sign and they may be sent home. These patients are able to tolerate adequate volumes of oral fluids, pass urine at least once every six hours. Patients Group B: These include patients with warning signs. These are patients wh...
Dengue is the most common mosquito-borne, viral disease in the world. Dengue virus is a single stranded positive polarity RNA virus, belongs to the family Flaviviridae. The Den-2 and Den-3 variants of dengue are active this year and of the two, Den-2 is more prominent, according to the Institute of Epidemiology, Disease Control and Researc...
Hand-foot-and-mouth disease (HFMD) is a common but highly contagious acute viral infection due to an enterovirus infection. The disease is most common under the age of 10, and most are under 5 years of age (95%). It can uncommonly affect adults and tends to be more severe in the elderly, immunocompromised, and pregnant women.  What is the cause...
Dengue is endemic in Bangladesh with recurrent outbreaks.  Health officials in Bangladesh have reported elevated dengue fever activity in Bangladesh during 2022. Dhaka and Chattogram has become a hotspot for dengue fever (DF).Why DF rising in August & September?•       The risk of dengue fever transmission in Bangladesh exists nationwide and...
Russian health officials have approved a single-dose version of the Sputnik V vaccine. Sputnik Light has showed nearly 80 per cent efficacy in tests. The single dose Sputnik Light vaccine demonstrated 79.4% efficacy according to analyzed data taken from 28 days after the injection was administered as part of Russia’s mass vaccination program...
In India, COVID-19 patients are developing a rare but fatal fungal infection, called "black fungus."  Two cases of black fungus have been detected at BIRDEM Hospital in patients who have recovered from Covid-19.According to an advisory issued by the Indian Council of Medical Research the following conditions in Covid-19 patients increase the...
Baricitinib plus remdesivir was superior to remdesivir alone in reducing recovery time and accelerating improvement in clinical status among patients with Covid-19, notably among those receiving high-flow oxygen or noninvasive ventilation. The combination was associated with fewer serious adverse events.
The U.S. Food and Drug Administration issued an emergency use authorization (EUA) for the drug baricitinib, in combination with remdesivir, for the treatment of suspected or laboratory confirmed COVID-19 in hospitalized adults and pediatric patients two years of age or older requiring supplemental oxygen, invasive mechanical...
Remdesivir, Hydroxychloroquine, Lopinavir and Interferon regimens appeared to have little or no effect on hospitalized COVID-19, as indicated by overall mortality, initiation of ventilation and duration of hospital stay. The mortality findings contain most of the randomized evidence on Remdesivir and Interferon, and are consistent with me...
In a paper on the interim findings on the four drugs, WHO's Solidarity trial researchers in 30 countries return a clear negative. The multi-country Solidarity trial anchored by the World Health Organization (WHO) has concluded that none of the four repurposed drugs that it examined — remdesivir, hydroxychloroquine (HCQ),...